Global Bronchodilators Market - 2022-2029

Market Overview

Bronchodilators Market size was valued US$ 42,649.87 million in 2021 and is estimated to reach US$ 66,314 million by 2029, growing at a CAGR of 5.9% during the forecast period (2022-2029).

Bronchodilators are the medications used for relaxing the muscles by opening the airways or widening the bronchial tubes in the lungs. These medications allow the air to move in and out of the lungs. Bronchodilators are effective in reducing the mucus from the lungs. These drugs are used to treat long-term conditions including asthma, and chronic obstructive pulmonary disease (COPD).

Market Dynamics

The bronchodilators market is driven by the rising prevalence of chronic obstructive pulmonary disease (COPD) and Asthma owing to the changing lifestyle, including smoking, tobacco consumption, and others.

Increasing advancements in technology and rising prevalence of chronic obstructive pulmonary disease are expected to drive market growth.

The bronchodilators market is driven by the rising prevalence of chronic obstructive pulmonary disease (COPD) and Asthma owing to the changing lifestyle, including smoking, tobacco consumption, and others. Chronic obstructive pulmonary disease (COPD) is a progressive life-threatening lung disease that causes breathlessness and predisposes to exacerbations and serious illness. According to the World Health Organization (WHO) in 2019, around 251 million people suffer from Chronic obstructive pulmonary disease (COPD) worldwide. Around 3.23 million people died due to Chronic obstructive pulmonary disease (COPD) worldwide.

The rise in the number of approvals of novel bronchodilators shall stimulate market growth. In April 2019, Circassia had received approval for its medication Duaklir to maintain chronic obstructive pulmonary disease (COPD). Duaklir is a combination of two long-acting bronchodilators, i.e., aclidinium bromide (400 mcg) and formoterol fumarate (12 mcg).

The increase in the research and development activities for the development of bronchodilators. The expected launch of the novel products shall stimulate market growth. For instance, Verona Pharma plc is developing the first-in-class development candidate, i.e., ensifentrine, an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4, a bronchodilator and an anti-inflammatory agent in a single compound. However, adverse events such as trembling, nervous tension, palpitations, muscle cramps, and others associated with bronchodilators hinder the market growth.

Adverse effects associated with bronchodilators is expected to hamper the market growth.

Adverse events such as trembling, nervous tension, palpitations, muscle cramps, and others associated with bronchodilators hinder the market growth.

Industry Analysis

The global bronchodilators Market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis, Product Innovation, Unmet Needs.

Segment Analysis

Drug type segment is expected to hold the largest market share in global bronchodilators market

The bronchodilators market is segmented based on the drug type: sympathomimetics, anticholinergics, a phosphodiesterase inhibitor, combination drugs, etc. The anticholinergics segment accounts for the highest market share owing to the higher uptake of anticholinergics as it is available in both long-acting and short-acting forms. The anticholinergics act by inhibiting the effect of acetylcholine on airways and nasal passages. The anticholinergics bronchodilators hamper cholinergic nerves' effect and lead the muscles to relax and dilate the airways. Atrovent HFA (ipratropium) and Spiriva Respimat (tiotropium) are the most commonly used anticholinergic bronchodilators. Atrovent HFA (ipratropium) is available as a metered-dose inhaler, and nebulizer solution and Spiriva Respimat (tiotropium) is a dry powder inhaler.

The phosphodiesterase inhibitor segment accounts for the positive market growth over the forecasted period. The phosphodiesterase inhibitor results in bronchodilation by increasing the intracellular cyclic adenosine monophosphate (cAMP). These inhibitors are effective in improving the diaphragm muscle contractility and stimulate the respiratory centre.

Further, the market is also classified based on the mode of action as long-acting bronchodilators and short-acting bronchodilators. The long-acting bronchodilators segment accounts for the highest market share due to the higher adoption of long-acting bronchodilators for controlling breathlessness among people with asthma and COPD. Long-acting bronchodilators are effective in increasing the efficacy of corticosteroids among patients with asthma. The market is dominated by the availability of long-acting bronchodilators, including the Advair, Dulera & Symbicort (a combination of a beta-agonist bronchodilator and an inhaled steroid), Serevent (salmeterol), Foradil (formoterol), Perforomist (formoterol solution for nebulizers), and others. The Serevent Diskus is used for the prevention of asthma attacks or exercise-induced bronchospasm. It is also used to treat chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis.

The short-acting bronchodilators segment is expected to have positive market growth over the forecasted period. Short-acting bronchodilators are used to treat sudden symptoms, including wheezing, shortness of breath, and chest tightness. These bronchodilators are the quick, active Albuterol, levalbuterol, and pirbuterol are the short-acting bronchodilators present in the market. These bronchodilators relieve acute asthma symptoms or attacks very quickly by opening airways. Short-acting bronchodilators are effective for the treatment of patients with asthma.

Geographical Analysis

North America region holds the largest market share in the global bronchodilators market

By region, the bronchodilators market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all the regions, North America dominated the bronchodilators market due to the high prevalence of chronic obstructive pulmonary disease (COPD) and Asthma. According to the Office of Disease Prevention and Health Promotion (ODPHP), around 14.8 million adults suffer from the chronic obstructive pulmonary disease (COPD) in the United States in 2020. And 25 million are suffering from asthma. The prevalence of chronic obstructive pulmonary disease (COPD) increases with rising exposure to air pollutants, genetic factors, and respiratory infections. The market is witnessing technological advancement in the development of bronchodilators. The high investment in the research and development activities for bronchodilators shall stimulate market growth.

The Asia Pacific region is expected to have positive market growth due to the increasing number of developing bronchodilators. There is an increase in the availability of bronchodilators. China is expected to have the highest market growth due to a high proportion of the smoking population and tobacco producers. These factors increase the risk of developing the chronic obstructive pulmonary disease (COPD) and Asthma. The growing awareness regarding the use of bronchodilators shall fuel the market growth over the forecasted period.

Competitive Landscape

The bronchodilators market is highly competitive with the presence of several international and local markets. Abbott Laboratories, AstraZeneca plc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc, and Sanofi are the leading market players with significant market share.

Companies are using novel product approvals, new product development, market expansion, and product diversification strategies for holding their position in the market.

The companies enter into collaborations, mergers, strategic partnerships, and acquisitions to increase the demand for bronchodilators and their expansion across the globe. For instance, in June 2019, Theravance Biopharma and Mylan had expanded the Yupelri (Revefenacin) development and commercialization agreement to include China and adjacent territories.

Key Companies to Watch

Abbott Laboratories:

Overview: Abbott is American multinational company that develops medical devices and healthcare products. It was founded in 1888 and is headquartered in Illinois, United States. Their products and services include medical devices, diagnostics, nutritional products and branded generic medicines.

Product Portfolio:

Leutrol: It is a drug used for asthma. It inhibits 5-lipoxygenase enzyme from eicosanoid synthesis pathway which blocks synthesis of leukotriene.

Key Developments: In Oct 2020, Abbott got emergency use authorization for their COVID-19 IgM antibody blood test from the FDA.

The global bronchodilators market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.